Pfizer (NY:PFE)

As bond yields climb amid record U.S. debt, Vanguard's BSV and VCIT ETFs offer TTM yields of about 4% and 5%, respectively, with potential for rising monthly distributions.

Topics Intellectual Property

These S&P500 stocks are the most active in today's session ↗

September 24, 2026

Via Chartmill

Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income ↗

September 24, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Topics Bonds ETFs

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks ↗

Topics Intellectual Property Regulatory Compliance

September 24, 2026

Via Chartmill

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗

September 23, 2026

Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? ↗

Topics ETFs

September 23, 2026

These are among the highest-yielding stocks on the S&P 500.

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

Topics Stocks

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief...

Topics Economy

Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline ↗

September 22, 2026

These companies are committed to rewarding shareholders.

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

September 22, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

September 22, 2026

CoreWeave vs. D-Wave Quantum: Is the AI Giant or the Quantum Computer Upstart the Better Stock Investment? ↗

September 21, 2026

Both are high-growth bets on unproven cutting-edge technologies.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Topics Artificial Intelligence

1 Mid-Cap Stock with Exciting Potential and 2 We Turn Down

September 21, 2026

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock? ↗

September 20, 2026

Pfizer's rebound is well underway.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Topics Intellectual Property World Trade

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

Pfizer has a history of developing treatments that generate billions in sales.

Topics Intellectual Property

Is Pfizer an Excellent Dividend Stock to Buy? ↗

September 19, 2026

They have a knack for increasing their dividends even when facing challenges.

3 Dividend Stocks to Buy and Hold for 10 Years ↗

September 18, 2026

I'd buy Energy Transfer and Verizon stocks, and avoid Pfizer.

Topics Intellectual Property

2 High-Yield Dividend Stocks to Buy and 1 to Avoid ↗

September 18, 2026

Income investors shouldn't be too worried about the pharma giant cutting its dividend.

Topics Artificial Intelligence Intellectual Property

Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive. ↗

September 17, 2026

The company is still looking to bounce back after the beating it took in recent years.

Topics Earnings Intellectual Property

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Topics Economy

1 Stock Under $50 to Target This Week and 2 That Underwhelm

September 16, 2026

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

September 15, 2026

Via Chartmill

IP Group H1 Earnings Call Highlights ↗

September 15, 2026

IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio...

Analysts think Alnylam could rebound strongly over the next 12 months.

Topics Earnings Initial Public Offering

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining...

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗

September 14, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Topics Intellectual Property World Trade

3 Healthcare Stocks That Fall Short

September 14, 2026

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

How Concerned Should Income Investors Be About Pfizer's Dividend? ↗

September 12, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...

Topics Intellectual Property

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗

September 12, 2026

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo...

Topics ETFs

1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges

September 11, 2026